肿瘤学标准治疗中的精准医学。
Precision medicine in oncology standard of care.
作者信息
Adams Lynn
出版信息
Semin Oncol Nurs. 2014 May;30(2):100-8. doi: 10.1016/j.soncn.2014.03.003.
OBJECTIVES
To review the histologic subtypes and staging of non-small cell lung cancer and metastatic melanoma, as well as the molecular markers used to direct standard therapy.
DATA SOURCES
Book chapters and journal articles from medical and nursing literature, as well as published clinical guidelines.
CONCLUSION
Patients with metastatic non-small cell lung cancer and metastatic melanoma have had a paucity of treatment options, most fraught with toxicity with limited benefit. Increased understanding of tumor genetics and molecular markers has expanded the treatment options for these patients, often providing them with durable responses and improved quality of life.
IMPLICATIONS FOR NURSING PRACTICE
To provide education and support to their patients, nurses caring for these patients need to understand the role that genetics and molecular markers play in directing these therapies.
目的
回顾非小细胞肺癌和转移性黑色素瘤的组织学亚型及分期，以及用于指导标准治疗的分子标志物。
数据来源
医学和护理文献中的书籍章节、期刊文章以及已发表的临床指南。
结论
转移性非小细胞肺癌和转移性黑色素瘤患者的治疗选择有限，且大多充满毒性且获益有限。对肿瘤遗传学和分子标志物的深入了解扩大了这些患者的治疗选择，通常能为他们带来持久缓解并改善生活质量。
对护理实践的启示
为向患者提供教育和支持，护理这些患者的护士需要了解遗传学和分子标志物在指导这些治疗中所起的作用。
Zotero 插件